Selective killing tumor cells, advanced liver cancer, bowel cancer liver metastasis has a new treatment method!

(Health Times reporter Mao Yuanyuan)
" China has the highest number of new cases of colorectal cancer in the world, but also faces the challenge of relapse metastasis, insensitivity of chemotherapy, 5-year survival rate of only about 65%, so we urgently need to find new markers to help treat patients. Professor Li Menghong, Executive Director of the Institute of Gastroenterology, Zhongshan University, introduced.
recently, Guangdong, Hong Kong and Macao Great Bay Area Oncologists Forum held in Guangzhou, the first "Guangdong, Hong Kong and Macao Great Bay Area Oncologists Group - Zhongshu Oncologist Group" officially landed in Guangzhou, and the introduction of advanced liver cancer, bowel cancer liver metastasis treatment of new means - SIRT (90 microspheres).
, Huang Jiaming, director of the Oncology Department of the Hong Kong Health Cancer Center, suggested in the keynote speech "SirT of liver metastasis of colorectal cancer" that SIRT is a selective inthertomerapy, a special radiotherapy, sirT treatment is a special radiation treatment, SIRT treatment is through blood vessels to transport high doses of radioactive particles to a specific location of the body, selectively kill tumor cells, to normal tissues and organs with little harm. The niobium 90 microsphere is its commonly used therapeutic carrier.
it is understood that SIRT (90 microspheres) treatment in 2002 through the United States FDA approval, in 2003 through the European Union (EU) approval, at present, there are a number of "EU, United States, Singapore, China (domestic, Hong Kong, Taiwan) and other medical association guidelines recommended as the treatment of liver malignant tumors."
's PRET (90 microspheres) treatment of indications include:
primary liver cancer, such as non-surgical primary liver cancer first-line treatment, especially with patients with transgtic cancer hydrants;
liver metastasis for colorectal cancer, such as patients whose multi-line treatment is ineffective and surgically non-removable;
and other indications, including first-line treatment of non-removable bile duct cancer; combined octreotide for the treatment of neuroendocrine tumor liver metastasis; liver metastasis for solid tumors that worsen the disease and are ineffective for multiple chemotherapy drugs; elderly patients, frail patients, patients who are not tolerant of chemotherapy, etc.
.